Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Allarity Therapeutics (ALLR) Research & Development (2024 - 2025)

Allarity Therapeutics' Research & Development history spans 2 years, with the latest figure at $1.7 million for Q4 2025.

  • For Q4 2025, Research & Development fell 9.37% year-over-year to $1.7 million; the TTM value through Dec 2025 reached $6.6 million, up 8.28%, while the annual FY2025 figure was $6.6 million, 8.28% up from the prior year.
  • Research & Development reached $1.7 million in Q4 2025 per ALLR's latest filing, up from $1.2 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $2.3 million in Q2 2025 to a low of $1.0 million in Q3 2024.